IL17A and psoriasis: This multidirectional interplay, encapsulated in Fig. 1, provides a comprehensive framework that not only explains the clinical manifestations of psoriasis but also underpins current and emerging targeted therapies aimed at interrupting specific nodes of the inflammatory circuit most notably the IL-23/IL-17 axis, TNF-α, and JAK/STAT pathways.